Status Proposed
Process STA 2018
ID number 3881

Provisional Schedule

Committee meeting: 1 20 January 2022
Expected publication 30 March 2022

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Janssen (daratumumab)
Others Department of Health and Social Care
  NHS England
  NHS Kingston CCG
  NHS Lancashire North CCG
  Welsh Government
Patient carer groups Anthony Pilcher Bone Cancer Trust
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Myeloma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Psychosocial Oncology Society
  British Society for Haematology
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Health Lumen
  UK Myeloma Forum
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Aspen (dexamethasone)
  Celgene (lenalidomide, pomalidomide)
  Focus Pharmaceuticals (dexamethasone)
  Hameln Pharmaceuticals (dexamethasone)
  Hospira (dexamethasone)
  Janssen (bortezomib)
  Merck, Sharp and Dohme (dexamethasone)
  Novartis (panobinostat)
  Rosemont Pharmaceuticals (dexamethasone)
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bone Cancer Research Trust
  Bone Research Society
  Cochrane Haematological Malignancies Group
  Geonomics England
  Institute of Cancer Research
  Leukaemia UK
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
13 September 2021 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance